Results 31 to 40 of about 78,472 (208)

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist [PDF]

New England Journal of Medicine, 2009
Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone.We studied nine children from six families who had neonatal onset of ...
Deborah L. Stone, Peter K. Gregersen, Paul Babyn, Daniel C. Douek, Ulf Tedgård, Daniel L. Kastner, Dawn Chapelle, Kamal Ohson, Matthew G. Booty, Barbara Yang, Massimo Gadina, Netanya G. Sandler, Elaine F. Remmers, A. Elisabeth Hak, John A. Butman, Arian Laurence, Ivona Aksentijevich, Benjamin D. Korman, P. Martin van Hagen, Hatem El-Shanti, Chyi-Chia Richard Lee, Seth L. Masters, Maria L. Turner, Edward W. Cowen, Proton Rahman, Marc Nicholson, Xinyu Bing, Jacob D. Estes, Suvimol Hill, Polly J. Ferguson, Marjan Huizing, Elena Pope, Paul Dancey, Karyl S. Barron, Nicole Plass, R. M. Laxer, Annet van Royen-Kerkhoff, Joost Frenkel, Raphaela Goldbach-Mansky, Rayfel Schneider, Gillian I. Clarke, Tuyet-Hang Pham   +41 more
openaire   +4 more sources

Interleukin-1 receptor antagonist inhibits the hypercalcemia mediated by interleukin-1

Journal of Bone and Mineral Research, 1993
Abstract Recently, the effects of interleukin-1 (IL-1) on bone resorption in organ culture have been shown to be inhibited by an interleukin-1 receptor antagonist (IL-1RA), a novel monocyte cytokine in the IL-1 family. IL-1RA, which binds to IL-1 receptors and inhibits many of the effects of IL-1α and β, has been purified, cloned, and ...
Lynda F. Bonewald, Gregory R. Mundy, I. Ross Garrett, Theresa A. Guise   +3 more
openaire   +3 more sources

Opium addiction increases interleukin 1 receptor antagonist (IL-1Ra) in the coronary artery disease patients. [PDF]

PLoS ONE, 2012
BACKGROUND: There is evidence that opium addiction has immunosuppressant effects. Coronary artery disease (CAD) is a condition resulted from atherosclerosis which is dependent on the immune response.
Habibollah Saadat, Seyed Ali Ziai, Maryam Ghanemnia, Mohammad Hasan Namazi, Morteza Safi, Hosein Vakili, Ali Dabbagh, Omid Gholami   +7 more
doaj   +1 more source

Interpretation on the 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist

Xiehe Yixue Zazhi, 2023
Interleukin-1 mediated autoinflammatory diseases, a large class of autoinflammatory diseases characterized by increased release of interleukin-1 or activation of the interleukin-1 pathway, mainly include familial Mediterranean fever, cryopyrin-associated
ZHOU Yu, SONG Hongmei
doaj   +1 more source

Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension

Frontiers in Immunology, 2019
Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions.
Christine B. Bui, Christine B. Bui, Magdalena Kolodziej, Emma Lamanna, Kirstin Elgass, Arvind Sehgal, Arvind Sehgal, Ina Rudloff, Ina Rudloff, Daryl O. Schwenke, Hirotsugu Tsuchimochi, Maurice A. G. M. Kroon, Maurice A. G. M. Kroon, Steven X. Cho, Steven X. Cho, Anton Maksimenko, Marian Cholewa, Philip J. Berger, Philip J. Berger, Morag J. Young, Jane E. Bourke, James T. Pearson, James T. Pearson, Marcel F. Nold, Marcel F. Nold, Claudia A. Nold-Petry, Claudia A. Nold-Petry   +26 more
doaj   +1 more source

Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor [PDF]

Journal of Biological Chemistry, 1991
The interleukin-1 receptor antagonist (IL-1ra) inhibits the binding of interleukin-1 (IL-1) to T-cell lines possessing the type I IL-1 receptor; evidence has been published (Carter, D. B., Deibel, M. R. J., Dunn, C. J., Tomich, C. S., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., Harris, P. K. W., Yem, A.
Eric V. Granowitz, Javier Mancilla, Charles A. Dinarello, Barton D. Clark   +3 more
openaire   +2 more sources

A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum

Orthopedic Reviews, 2013
The purpose of the present study was to investigate the effect of intra-articular injections of autologous conditioned serum on human hip osteoarthritis and to test whether a potential treatment effect might be increased by additional injections of ...
Axel W.A. Baltzer, Martin S. Ostapczuk, Daniel Stosch, Florian Seidel, Markus Granrath   +4 more
doaj   +1 more source

Autoinflammatory Mechanisms in Crystal-Induced Arthritis

Frontiers in Medicine, 2020
Crystal-induced arthritides have been classified as “type-1 autoinflammatory diseases” for their main features which resemble those of the monogenic autoinflammatory syndromes.
Francesca Oliviero, Sara Bindoli, Anna Scanu, Eugen Feist, Andrea Doria, Paola Galozzi, Paolo Sfriso   +6 more
doaj   +1 more source

Full-length and N-terminally truncated recombinant interleukin-38 variants are similarly inefficient in antagonizing interleukin-36 and interleukin-1 receptors

Cell Communication and Signaling
Background Interleukin (IL)-38 is an IL-1 family cytokine that was proposed to exert anti-inflammatory effects. However, its mechanisms of action are not well understood and the identity of the IL-38 receptor(s) remains debated.
Alejandro Diaz-Barreiro, Dominique Talabot-Ayer, Arnaud Huard, Gea Cereghetti, Jenna Tonacini, Mike Maillasson, Antonio Francés-Monerris, Erwan Mortier, Gaby Palmer   +8 more
doaj   +1 more source

Tocilizumab improved clinical symptoms of a patient with systemic tophaceous gout who had symmetric polyarthritis and fever: An alternative treatment by blockade of interleukin-6 signaling

SAGE Open Medical Case Reports, 2014
Chronic tophaceous gout is the end stage of gout. We employed a blockade of interleukin-6 signaling therapy by tocilizumab instead of anakinra, an interleukin-1 receptor antagonist, for a 61-year-old Japanese woman diagnosed with tophaceous gout ...
Sho Mokuda, Masamoto Kanno, Kiyoshi Takasugi, Chikara Okumura, Yuki Ito, Junya Masumoto   +5 more
doaj   +1 more source